ELMO: Early Caries Lesion Management Observational Study

Sponsor
CareQuest Institute for Oral Health (Other)
Overall Status
Recruiting
CT.gov ID
NCT04933331
Collaborator
(none)
744
4
36.8
186
5.1

Study Details

Study Description

Brief Summary

The purpose of this observational study is to assess the effectiveness of Curodont Repair Fluoride Plus (CRFP) compared to other tooth-specific treatments (silver diamine fluoride (SDF), sealants, or other FDA-approved treatments) in preventing progression to cavitation in patients with at least one early non-cavitated dental caries lesion.

The study will also evaluate the effectiveness of CRFP in comparison to no tooth-specific treatment control groups, including whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste; and no treatment, on caries arrest and in preventing progression to cavitation in patients with at least one early non-cavitated dental lesion.

Condition or Disease Intervention/Treatment Phase
  • Drug: Curodont Repair Fluoride Plus
  • Device: Silver Diamine Fluoride
  • Device: Glass Ionomer Sealant
  • Device: Fluoride varnish
  • Drug: Fluoride toothpaste

Detailed Description

Study subjects will be enrolled upon diagnosis of at least one ADA Caries Classification system "initial" caries lesion. Subjects will be further sorted into study cohorts based on the non-invasive treatment option they select. The early lesions will be followed for 24 months after the date of the initial caries lesion diagnosis or the date of the first non-invasive treatment applied to the lesion.

Patients who choose CRFP will serve as the primary variable of interest. The primary objective is to assess the effectiveness of CRFP compared to other tooth specific treatments (SDF, sealants, or other FDA-approved treatments) in preventing progression to cavitation in initial dental lesions. The primary endpoint will be measured by the percentage of patients that require operative treatment for at least one early lesion noted at baseline during the following 24 months of observation.

The secondary objectives are to assess the effectiveness of CRFP compared to no tooth-specific treatment (including whole mouth treatments such as: fluoride varnish, fluoride foam, prescription toothpaste; other FDA-approved treatments; and no treatment) on 1.) caries arrest and 2.) preventing progression to cavitation in patients with at least one early dental lesion. The secondary endpoints will be measured by 1.) the percentage of patients that have caries arrest for at least one early lesion noted at baseline during the following 24 months of observation and 2.) the percentage of patients that require operative treatment for at least one early lesion noted at baseline during the following 24 months of observation.

Study Design

Study Type:
Observational
Anticipated Enrollment :
744 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
An Observational Multi-cite Study to Evaluate and Compare the Effectiveness of Various Tooth Specific Treatments in the Management of Early Caries Lesions
Actual Study Start Date :
Dec 7, 2020
Anticipated Primary Completion Date :
Jun 30, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Curodont Repair Fluoride Plus (Curodont) cohort

The effectiveness of Curodont treatment in this group will be compared to other treatment options and cohorts. Curodont will be professionally applied in the dental clinic. The treatment time takes about 5 minutes. Patients receive one professional dose application and be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months.

Drug: Curodont Repair Fluoride Plus
Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
Other Names:
  • Curolox
  • p11-4
  • Device: Fluoride varnish
    2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

    Drug: Fluoride toothpaste
    Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
    Other Names:
  • Prevident
  • Clinpro
  • Other tooth-specific initial lesion interventional treatments cohort(s)

    Silver Diamine Fluoride (SDF). The treatment time is about 2 minutes. Glass Ionomer Sealants: The treatment time takes about 5 minutes per sealant. Typically four sealants are completed in one visit. All patients will be provided with homecare instructions and will be instructed to return for regular dental visits and exams according to the frequency determined by their dental team, usually every 6 months.

    Device: Silver Diamine Fluoride
    Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
    Other Names:
  • SDF
  • Silver Nitrate
  • Device: Glass Ionomer Sealant
    A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
    Other Names:
  • GI Sealant
  • Device: Fluoride varnish
    2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

    Drug: Fluoride toothpaste
    Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
    Other Names:
  • Prevident
  • Clinpro
  • Control cohort, no tooth-specific treatment or whole mouth treatment.

    If a patient or their caregivers choose no tooth-specific treatment, they will be included in the control cohort. This group includes patients who chose to receive no treatment at all, as well as those who choose whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste.

    Device: Fluoride varnish
    2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

    Drug: Fluoride toothpaste
    Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
    Other Names:
  • Prevident
  • Clinpro
  • Orthodontic cohort

    Patients in active orthodontic care will be analyzed separately from other patients to account for the impact of orthodontic appliances on treatment outcomes. Orthodontic appliances are recognized by the American Dental Association Caries Risk Assessment as a risk factor for caries because they create dental plaque stagnation areas that are difficult to clean. Initial caries lesions are very frequently seen immediately surrounding orthodontic brackets (braces), yet continued plaque stagnation over the treated areas may heavily influence the success of any treatment. All groups/cohorts above will be represented in the orthodontic cohort in parallel.

    Drug: Curodont Repair Fluoride Plus
    Self-assembling peptide that integrates calcium and phosphate ions into the same hydroxyapatite that the enamel is made of through biomimetic re-mineralization. Amino acid sequence: CH3,COQQRFEWEFEQQ,NH2.
    Other Names:
  • Curolox
  • p11-4
  • Device: Silver Diamine Fluoride
    Silver diamine fluoride 38% is indicated for the treatment of dentinal hypersensitivity. SDF works by killing pathogenic organisms and hardens softened dentin making it more acid and abrasion resistant. The ADA recommends the use of SDF in treating early lesions.
    Other Names:
  • SDF
  • Silver Nitrate
  • Device: Glass Ionomer Sealant
    A hydrophilic type of sealant material made with water, polymeric acid, and glass power. These sealants release fluoride over time which also helps protect against and repair initial caries lesions. The ADA recommends the use of sealants in treating occlusal early lesions.
    Other Names:
  • GI Sealant
  • Device: Fluoride varnish
    2.5% Sodium Fluoride Varnish which reduces dentinal hypersensitivity by occluding dentinal tubules.

    Drug: Fluoride toothpaste
    Prescription sodium fluoride toothpaste medicament used in place of regular toothpaste. It works by making the teeth stronger and more resistant to caries.
    Other Names:
  • Prevident
  • Clinpro
  • Outcome Measures

    Primary Outcome Measures

    1. To assess the effectiveness of CRFP compared to other tooth specific treatments in preventing progression to cavitation. [24 months]

      The percentage of patients treated with CRFP that require operative treatment for at least one early lesion within the 24 months.

    Secondary Outcome Measures

    1. To assess the effectiveness of CRFP compared to no tooth specific treatments (including whole mouth treatments) on caries arrest. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of patients that have caries arrest for at least one early lesion noted at baseline during the 24 months of observation from baseline.

    2. To assess the effectiveness of CRFP compared to no tooth specific treatment (including whole mouth treatment) in preventing progression to cavitation. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of patients that require operative treatment for at least one early lesion noted at baseline during the 24 months of observation from baseline.

    Other Outcome Measures

    1. To assess the effectiveness of SDF compared to no tooth specific treatment (including whole mouth treatment) on caries arrest in patients with at least one early dental lesion. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of lesions treated with SDF that have caries arrest for at least one early lesion noted at baseline during the 24 months of observation from baseline.

    2. To assess the effectiveness of SDF (silver diamine fluoride) compared to no tooth specific treatment (including whole mouth treatment) in preventing progression to cavitation. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of lesions treated with SDF that require operative treatment for at least one early lesion noted at baseline during the 24 months of observation from baseline.

    3. To assess the effectiveness of sealants compared to no tooth specific treatment (including whole mouth treatment) in preventing progression to cavitation. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of lesions treated with sealants that require operative treatment for at least one early lesion noted at baseline during the 24 months of observation from baseline.

    4. To assess the effectiveness of CRFP compared to sealants in preventing progression to cavitation. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of lesions treated with CRFP that require operative treatment compared to those treated with sealants during the 24 months of observation from baseline.

    5. To assess the effectiveness of CRFP compared to SDF in preventing progression to cavitation. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of lesions treated with CRFP that require operative treatment compared to those treated with SDF during the 24 months of observation from baseline.

    6. To assess the effectiveness of CRFP compared to SDF (silver diamine fluoride) on caries arrest in patients with at least one early dental lesion. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of lesions treated with CRFP that have caries arrest compared to those treated with SDF that have caries arrest during the 24 months of observation from baseline.

    7. To assess the effectiveness of sealants compared to SDF (silver diamine fluoride) in preventing progression to cavitation in patients with at least one early dental lesion. [Baseline, 6 months, 12 months, 18 months, 24 months]

      The percentage of lesions treated with SDF that require operative treatment compared to those treated with sealants during the 24 months of observation from baseline.

    8. To assess the effectiveness of tooth specific treatments in patients who are actively undergoing orthodontic care and have at least one early dental lesion. [Baseline, 6 months, 12 months, 18 months, 24 months]

      A comparison of lesions that have caries arrest or require operative treatment for early lesion interventions during the 24 months of observation from baseline.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    4 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • All patients with permanent teeth who are diagnosed with at least one American Dental Association Caries Classification System (ADACCS) "Initial" caries lesion in a permanent tooth, will be included in this analysis.
    Exclusion Criteria:
    • Primary teeth

    • Permanent teeth with ADACCS "Moderate" or "Advanced" caries lesions

    • Healthy/ ADACCS "Sound" teeth

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sarrell Dental Clinic Dothan Alabama United States 36303
    2 DentaQuest (Advantage Dental) Oral Health Center Westborough Massachusetts United States 01581
    3 Advantage Dental Oral Health Center Bend Oregon United States 97701
    4 Community Dental Care Dallas Texas United States 75246

    Sponsors and Collaborators

    • CareQuest Institute for Oral Health

    Investigators

    • Principal Investigator: Laura J Skaret, BS, CareQuest Innovation Partners

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Laura Skaret, Laura Skaret, BSDH, Clinical Innovation Manager, CareQuest Institute for Oral Health
    ClinicalTrials.gov Identifier:
    NCT04933331
    Other Study ID Numbers:
    • DQCI003
    First Posted:
    Jun 21, 2021
    Last Update Posted:
    Nov 19, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Laura Skaret, Laura Skaret, BSDH, Clinical Innovation Manager, CareQuest Institute for Oral Health
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 19, 2021